These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21107655)

  • 1. Two hour bivalirudin infusion after PCI for ST elevation myocardial infarction.
    Anderson PR; Gogo PB; Ahmed B; Straight F; Terrien EF; Watkins MW; El Gharib N; Dauerman HL
    J Thromb Thrombolysis; 2011 May; 31(4):401-6. PubMed ID: 21107655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bleeding complications with regional adaptation of a prolonged bivalirudin regimen for ST-elevation acute myocardial infarction.
    Mueller E; Prabhu W; Desarno M; Sundaran P; Dauerman H
    Am J Cardiol; 2012 Dec; 110(11):1607-12. PubMed ID: 22901969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.
    Shelton R; Eftychiou C; Somers K; Liu A; Burton-Wood N; Anderson M; Makri L; Blaxill J; McLenachan J; Wheatcroft S; Greenwood J; Blackman D
    EuroIntervention; 2013 May; 9(1):118-24. PubMed ID: 23410540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of postprocedural full-dose infusion of bivalirudin on acute stent thrombosis in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real-world population.
    Wang H; Liang Z; Li Y; Li B; Liu J; Hong X; Lu X; Wu J; Zhao W; Liu Q; An J; Li L; Pu F; Ming Q; Han Y
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28083915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
    Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
    J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study.
    Chang CC; Chichareon P; Modolo R; Takahashi K; Kogame N; Tomaniak M; Gao C; Royaards KJ; Cequier A; Oldroyd K; Steg PG; Hamm C; Jüni P; Valgimigli M; Windecker S; Onuma Y; Stables RH; Jan van Geuns R; Serruys PW
    Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):22-30. PubMed ID: 31841136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged High-Dose Bivalirudin Infusion Reduces Major Bleeding Without Increasing Stent Thrombosis in Patients Undergoing Primary Percutaneous Coronary Intervention: Novel Insights From an Updated Meta-Analysis.
    Fahrni G; Wolfrum M; De Maria GL; Banning AP; Benedetto U; Kharbanda RK
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27451466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
    Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P;
    Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study.
    Garcia-Garcia HM; Adamo M; Soud M; Yacob O; Picchi A; Sardella G; Frigoli E; Limbruno U; Rigattieri S; Diletti R; Boccuzzi G; Zimarino M; Contarini M; Russo F; Calabrò P; Andò G; Varbella F; Garducci S; Palmieri C; Briguori C; Karagiannis A; Valgimigli M
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1156-1171. PubMed ID: 31883294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
    Wang H; Li Y; Cong H; Ding S; Liu B; Li L; Chen Y; Jia S; Jing Q; Zhao X; Liu H; Liang Z; Li J; Bao D; Han Y
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1157-1165. PubMed ID: 27677411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
    Witzenbichler B; Mehran R; Guagliumi G; Dudek D; Huber K; Kornowski R; Stuckey TD; Fahy M; Parise H; Stone GW
    JACC Cardiovasc Interv; 2011 Jul; 4(7):760-8. PubMed ID: 21777884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography).
    Clemmensen P; Wiberg S; Van't Hof A; Deliargyris EN; Coste P; Ten Berg J; Cavallini C; Hamon M; Dudek D; Zeymer U; Tabone X; Kristensen SD; Bernstein D; Anthopoulos P; Prats J; Steg PG
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):214-220. PubMed ID: 25616927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).
    Stone GW; Clayton T; Deliargyris EN; Prats J; Mehran R; Pocock SJ
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):15-20. PubMed ID: 24140664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bivalirudin versus heparin, without glycoprotein inhibition, in percutaneous coronary intervention: A comparison of ischemic and hemorrhagic outcomes over 10years.
    Chaudry HI; Curran TB; Andrus BW; Conley SM; DeVries JT
    Cardiovasc Revasc Med; 2018; 19(3 Pt B):338-342. PubMed ID: 29055661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalirudin with a post-procedure infusion versus heparin monotherapy for the prevention of stent thrombosis.
    Shah R; Latham SB; Porta JM; Naz A; Matin K; Rao SV
    Catheter Cardiovasc Interv; 2019 Aug; 94(2):210-215. PubMed ID: 30636368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
    Mehran R; Lansky AJ; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Wong SC; Nikolsky E; Gambone L; Vandertie L; Parise H; Dangas GD; Stone GW;
    Lancet; 2009 Oct; 374(9696):1149-59. PubMed ID: 19717185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalirudin in ST-segment-elevation myocardial infarction: for better or worse?
    Mavrakanas TA; Chatzizisis YS
    Expert Rev Cardiovasc Ther; 2015; 13(8):893-5. PubMed ID: 26138859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
    Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
    Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.